A Randomized, double-blind, placebo-controlled, multicenter phase III study of RAD001 Adjuvant Therapy in Poor Risk with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching PlaceboAfter Patients Have Achieved Complete Response with First-line Rituximab Chemotherapy
2022-06-29
عنوان الدراسة
A Randomized, double-blind, placebo-controlled, multicenter phase III study of RAD001 Adjuvant Therapy in Poor Risk with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching PlaceboAfter Patients Have Achieved Complete Response with First-line Rituximab Chemotherapy
داعم الدراسة
Novartis
دواء الدراسة
Everolimus
رقم بروتوكول الدراسة
CRAD001N2301
حالة الدراسة
Completed
موقع الدراسة
KFSH
مرحلة الدراسة
3
评论与建议
如对政府服务有任何咨询或意见,请填写所需信息。